BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2003

View Archived Issues

Once-monthly octreotide acetate improves visual acuity in cystoid macular edema

Read More

Antiviral and antiinflammatory effects for N-chlorotaurine in adenoviral keratoconjunctivitis

Read More

Tripep to acquire Isconova

Read More

Development of CEL-1000 for herpes simplex funded by NIAID

Read More

Initiation of phase I clinical trial of TTS-CD3 in patients with NSCLC

Read More

PDL discontinues development of anti-IL-4 antibody for asthma

Read More

NeoPharm granted FDA permission for LEP-ETU clinical trial

Read More

Xcyte T-cell product enters phase I/II trial in multiple myeloma

Read More

Abgenix and Sosei enter CRTH2-targeting antibody development agreement

Read More

Genentech and ABC(2) to collaborate on Tarceva brain cancer trial

Read More

Dendreon uses telomerase in new cancer immunotherapy

Read More

Emisphere's oral insulin candidate enters clinical testing

Read More

Vancomycin-cephalosporin conjugates prepared and tested at Theravance

Read More

Roche describes another series of adenosine A2A receptor modulators

Read More

Tularik reports IRAK inhibitors and their use in inflammatory, proliferative and immune disorders

Read More

Dual 5-HT reuptake inhibitors/5-HT1A agonists described in Wyeth patent

Read More

Novel H3 receptor modulators designed by Novo Nordisk and Boehringer Ingelheim team

Read More

Debio presents new camptothecin prodrugs in recent patent

Read More

New PDE5 inhibitors under study at Merck KGaA

Read More

Enanta claims new ciclosporin analogues with utility in asthma therapy

Read More

Pharmacia (now Pfizer) presents new 5-HT6 receptor ligands

Read More

Novartis scientists discover novel steryl sulfatase inhibitors for acne, hirsutism, etc.

Read More

Cozaar approved for diabetics with kidney disease and high blood pressure in Canada

Read More

Chugai research operations to close in U.S.

Read More

Second Merck antibody advances to phase II trials

Read More

Licensing opportunity from Milkhaus: ML-04 for BPH and prostatitis

Read More

Multivalent Fab molecule targeting ICAM-1 prevents HRV infection

Read More

SUN-C8079, a new NF-kB inhibitor, evaluated in vitro and in vivo

Read More

New antibacterial agent activated by L-tryptophanase, a bacteria-specific enzyme

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing